Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations

10 Sept 2021

Abstract excerpt

SGLT2 (sodium-glucose cotransporter 2) inhibitors are a new class of antihyperglycaemic drugs that act on the proximal tubules of the kidney. They have shown efficacy in the management of diabetes mellitus type 2 and their cardiovascular and renal safety have been extensively investigated and confirmed in clinical trials. However, inter-individual differences in response to treatment with SGLT2 inhibitors may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Management and Research
Share to Diabetes Treatment and Management
Share to Pancreatic function and diabetes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34575958
DOI: 10.3390/ijms22189800

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic VariationsPMID 34575958Read ↗

Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarkerSemantic proximity Read ↗

Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.Semantic proximity Read ↗

The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Semantic proximity Read ↗

Pharmacogenetics of Type 2 Diabetes—Progress and ProspectsSemantic proximity Read ↗

Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphismsSemantic proximity Read ↗

Genetics of Response to Canagliflozin (GRC) Study: Rationale, Design, and Pharmacodynamic Responses.Semantic proximity Read ↗

Search for a Functional Genetic Variant Mimicking the Effect of SGLT2 Inhibitor Treatment.Semantic proximity Read ↗

Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 DiabetesSemantic proximity Read ↗

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity Read ↗

Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicineSemantic proximity Read ↗

Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis.Semantic proximity Read ↗

A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 DiabetesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.